Evidence map›Paper›PMID 26573510›Full record

ArticleJournal of cancer research and clinical oncology2016

Caveolae as a target to quench autoinduction of the metastatic phenotype in lung cancer.

David John Garnett

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

David John GarnettInstitute of Science Technology in Medicine, Keele University, Keele, Staffordshire, ST5 5BG, UK. d.j.garnett@keele.ac.uk.
Keele University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMevalonate pathway inhibitors are potentially useful chemotherapeutic agents showing growth inhibition and pro-apoptotic effects in cancer cells. The effects of statins and bisphosphonates on cancer growth are attributed to a reduction in protein isoprenylation. Post-translational modification and activation of GTPase binding Ras superfamily permit the recruitment of these signal proteins to membranes where they mediate the cancer phenotype. Here, the effects of three inhibitors of the mevalonate pathway and one specific inhibitor of sterol regulatory element-binding proteins were studied in both an ER-negative, Ras-inactive breast (MDA-MB-231) and lung adenocarcinoma (CaLu-1) cells in vitro.

methodsTreated cells were subject to genome-wide gene expression profiling. A gene subset was established so that the epithelial to mesenchymal transition (EMT) could be observed and compared with signalling protein shifts.

resultsWithin the subset, some genes normally up-regulated during EMT were asymmetrically reduced by a Δ-24 DHCR inhibitor in the lung cells. Signalling proteins associated with caveolae were down-regulated by this oxidoreductase inhibitor, while those associated with membrane rafts were up-regulated.

conclusionsThis study decouples isoprenylation effects from cholesterol events per se. The data support a hypothesis that caveolae are abolished by Δ-24 DHCR intervention and it is revealed that these microdomains are vital EMT signalling structures for lung cells but not ER- and Ras-negative breast cells. When signalling by extracellular signals is quenched by removal of the hydrophilic conduit provided by caveolae, the transcriptome responds by moving the cellular identity towards quiescence.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAntineoplastic AgentsCaveolaeCaveolin 1Cell Line, TumorEnzyme InhibitorsEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLung NeoplasmsMevalonic AcidNeoplasm MetastasisNerve Tissue ProteinsOxidoreductases Acting on CH-CH Group DonorsAntineoplastic AgentsCaveolin 1DHCR24 protein, humanEnzyme InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsMevalonic AcidNerve Tissue ProteinsOxidoreductases Acting on CH-CH Group DonorsProadifenCaveolaeGene expressionMetastasisProadifenStatins

Identifiers

PMID26573510
PMCPMC4751176
OpenAlexW2176747752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.